Outcomes of real-world complete responders after fixed-duration glofitamab in relapsed/refractory large B-cell lymphoma

Key Points

• To investigate the outcomes of patients with relapsed/refractory large B-cell lymphoma who achieved complete responses following glofitamab treatment.
• Observational analysis of patients treated with glofitamab.
• Assessment of response rates in relapsed/refractory large B-cell lymphoma.
• Evaluation of long-term outcomes in complete responders.
• High rates of complete response observed in treated patients.
• Significant improvement in survival rates noted among complete responders.
• Findings suggest durable effects of glofitamab in this patient population.